Health Technology Assessment (HTA) reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the U.S.–but only 67 have launched in a major market elsewhere. Understanding which companies and products are being impacted is critical competitive intelligence for strategic planners, market access, sales and marketing professionals.
Which companies are involved? What products have made the grade and where? When could new competitive threats emerge?
For answers turn to “Innovative Drugs: Mapping the Pricing and Reimbursement Landscape.” Comprising a detailed report and usable data set in Microsoft ExcelTM, this granular analysis exposes—at a product level—the pricing, reimbursement and status of innovative drugs in Australia, Canada, France, Germany and the U.K.
To find out more about this FirstWord report, click here.